Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

CyberPlayGround NetHappenings©1989

Educational CyberPlayGround, Inc
NetHappenings Newsletter
sign up/unsubscribe anytime here
https://cyberplayground.com
follow @cyberplayground @nethappenings

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints

It’s on the way to the FDA now for approval.

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine

 

Pfizer and BioNTech today provided an update on their COVID-19 vaccine. They now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study. Efficacy only drops to 94% in people over 65 years of age.

https://www.sciencemag.org/news/2020/11/covid-19-vaccine-trial-complete-pfizer-and-biontech-update-their-promising-result

Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.

Not to be outdone by a rival with a similar product, Pfizer and BioNTech today provided an update on the previously announced success of their COVID-19 vaccine. The U.S. pharma giant and its German biotech partner now report 95% efficacy for their vaccine candidate, drawing on the final analysis of a 43,000-person study. And don’t worry about the elderly not responding to the vaccine; the efficacy only drops to 94% in people over 65 years of age, the companies said in a press release.

The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

Amazon launches Amazon Pharmacy for prescription medicine delivery

Vitamin C Cuts COVID Deaths by Two-Thirds

Leave a Reply

Your email address will not be published. Required fields are marked *